Adcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosedSC
Surveyor Capital
Activity from announced rounds
Activity in this selection640-oxford-583a3e46
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $275M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSoley Therapeutics
Uses cells as sensors to uncover first-in-class medicines
$200MSeries C
Role not disclosed